Optic Neuritis and Mounjaro: What We Know So Far

What the post-marketing data and related GLP-1 findings actually show

The place to start is not the clinical trials, because the SURMOUNT programme (thousands of adults followed over 72 weeks) was designed to measure body weight, blood sugar, and cardiovascular outcomes. Eye health was not a primary or secondary endpoint, so the trial data neither confirms nor rules out an effect on the optic nerve. What has drawn attention is a different thread.

In 2024 the US Food and Drug Administration reviewed reports linking semaglutide (the active ingredient in Wegovy and Ozempic) to non-arteritic anterior ischaemic optic neuropathy, or NAION, a condition in which blood flow to the optic nerve is suddenly reduced. A study published in JAMA Ophthalmology found a statistically higher rate of NAION diagnoses in people using semaglutide compared with matched controls, though the absolute numbers were small and the researchers were careful to note that the association does not prove causation. Tirzepatide, as a dual GIP and GLP-1 receptor agonist, activates overlapping pathways, which is why similar questions have been raised about Mounjaro specifically, including reports of optic neuritis in post-marketing surveillance submitted to global pharmacovigilance databases.

The MHRA continues to monitor the class for new ocular signals; you can read about the reporting system for suspected side effects, including rare or unexpected ones, at the Yellow Card scheme. For now, the official position is watchfulness rather than a confirmed warning, but that does not mean the reports should be dismissed.

Why people taking Mounjaro may be at higher baseline ocular risk

A question our prescribers hear most weeks is whether a new symptom that appeared after starting Mounjaro was caused by the medicine or was already on its way. With optic neuritis and NAION, this is a genuinely hard question to untangle. The populations most likely to use tirzepatide (people living with obesity, type 2 diabetes, hypertension or dyslipidaemia) are also at meaningfully higher baseline risk of vascular events affecting the eye. Diabetic retinopathy, hypertensive retinopathy, and ischaemic optic neuropathy all share risk factors with the conditions tirzepatide treats.

This creates a confounding problem for researchers: if optic events are more common in GLP-1 users, is that because of the drug, or because of who is taking it? Rapid weight loss itself can, in some circumstances, temporarily worsen diabetic eye disease, a phenomenon noted in the context of other weight-loss interventions and captured in prescribing guidance for people with active proliferative retinopathy. The NHS medicines page for tirzepatide advises telling your prescriber about any eye conditions before starting treatment, and that remains the most practical safeguard.

If you are considering tirzepatide and have a pre-existing eye condition, that conversation with a prescriber is not a formality, it shapes the risk-benefit assessment for you specifically. Information about the broader range of tirzepatide considerations is on our tirzepatide overview page.

Urgent symptoms: when to act, and what to do

Optic neuritis typically presents as pain behind or around one eye, often worsened by eye movement, combined with blurred vision, loss of colour contrast, or a dark patch in the visual field. These symptoms can develop over hours to days. NAION tends to present differently: a sudden, painless loss of part of the visual field, often noticed on waking. Both are medical emergencies regardless of what medicines you are taking.

If you experience any sudden or progressive change in vision while on Mounjaro (including blurring, colour disturbance, eye pain, or loss of peripheral vision) the right move is to stop your injection and seek same-day medical review, either through your GP, an urgent ophthalmology service, or an NHS 111 call if no same-day GP appointment is available. Do not wait for a routine prescription review. If symptoms are severe or progressing rapidly, 999 or A&E is appropriate.

This is also the moment to report the event through the MHRA's Yellow Card scheme. Reports from patients, not just clinicians, are a key part of how rare signals get detected and investigated at a population level. If you are uncertain whether Mounjaro is playing a role, report it anyway, the scheme is designed for suspected events, not confirmed ones.

For context on the broader side-effect profile of Mounjaro, including the gastrointestinal effects that are far more commonly reported, our Mounjaro information page covers the full picture, and if you want to understand how stomach inflammation specifically can present during treatment, our gastritis and Mounjaro page goes into the detail. Separately, if you have questions about how joint conditions or inflammatory diseases interact with tirzepatide, the Mounjaro and arthritis page addresses some of the overlapping considerations.

Starting or continuing Mounjaro: the clinical assessment that matters

None of this should suggest that tirzepatide is unsafe for people without a documented eye condition. The evidence base for its benefits in weight management is robust: the SURMOUNT-1 trial reported an average body-weight reduction of around 20–21% at the 15mg dose over 72 weeks, a result that has translated into real clinical benefit for thousands of people. The risk-benefit calculation for most eligible adults remains clearly positive, and the MHRA has not issued a specific warning restricting tirzepatide use on optic nerve grounds.

What the emerging data underscores is the importance of having a qualified clinician (not an automated questionnaire) assess your personal history before treatment begins. Pre-existing eye conditions, diabetes with retinopathy, uncontrolled blood pressure, and a family history of ischaemic optic disease are all relevant disclosures, as are gut-related concerns such as those covered on our gastroenteritis and Mounjaro page, which can also affect whether treatment is well tolerated. At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber on the same day; no algorithm makes the call. A prescriber can weigh these factors properly and discuss whether additional monitoring makes sense for you.

If you are already on treatment elsewhere and want a second clinical opinion, or if you are thinking about starting and have questions about your eye health history, you can find more about how our clinical team approaches these assessments on the about us page and through our lead prescriber's profile. Cost is sometimes a factor in these decisions too, a fair overview of what private tirzepatide treatment involves financially is on our Mounjaro cost page. When you are ready to discuss your own situation, you can check your eligibility with our prescribers.